Scribe Therapeutics is engineering new therapeutics using CRISPR. The underlying causes of many genetic diseases can be treated through gene editing. Scribe is focusing on in vivo genetic editing, pioneering both viral and non-viral delivery technologies of highly active gene editors. Safe and effective editors are being identified in Scribe’s continually evolving and expanding genetic modification platform. This involves testing a suite of CRISPR technologies. Scribe’s first technology is X-editing (XE), an engineered molecule that provides in vivo genetic modification with greater activity, specificity and deliverability than traditional CRISPR. Scribe is now looking to apply XE to address diseases of significant unmet clinical need.